FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
about
Novel endogenous angiogenesis inhibitors and their therapeutic potentialPutative biomarkers and targets of estrogen receptor negative human breast cancerThe anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.FKBPL: a marker of good prognosis in breast cancer.Daidzein-estrogen interaction in the rat uterus and its effect on human breast cancer cell growthRALA-mediated delivery of FKBPL nucleic acid therapeuticsAssociation between estrogen receptor α gene (ESR1) PvuII (C/T) and XbaI (A/G) polymorphisms and hip fracture risk: evidence from a meta-analysis.The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Molecular cochaperones: tumor growth and cancer treatment.Biological relevance of Hsp90-binding immunophilins in cancer development and treatment.Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.Low-frequency nonsynonymous variants in FKBPL and ARPC1B genes are associated with breast cancer risk in Chinese women.
P2860
Q26781297-D6EC05BE-A8AD-49A7-B10D-45AFE3FA35D4Q27003285-12C2365F-F986-4AB7-9060-BA61F5753E42Q34606294-F6AA4B5D-C0AC-4416-B9ED-0689427CF5FCQ34688048-1D8D39E4-D2AB-493D-8FEC-5B0465EB0FB5Q35558306-655E3D53-5A96-4252-A1FF-08FFDA85C74AQ35828542-1965A2D7-CFF4-414A-AB1A-3FEF608F652DQ36469463-0F19C267-D5E4-4690-B5E7-0F60932B7887Q37013400-AEC9E231-A2C5-42C4-999C-0E2A74C96A3DQ37520069-0517463B-62F7-4552-B9F1-C4314177E3AFQ37856424-40DC5585-C2BB-4CDD-AE35-CD5E8EEED7DEQ38065993-DB6DF811-5CE3-4A61-9A92-D91497CC823EQ38166376-44088E0F-A0F5-4208-8FB4-CB4B0D774755Q38371280-DF4AD0A1-CAC3-4486-8BDC-B6D5B4D03984Q39115878-EFB79271-D292-42AA-8C59-5746CDC9FE62Q51457150-9B3FEECC-9ADD-41C8-BFAF-A92947A70F20
P2860
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@ast
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@en
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@nl
type
label
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@ast
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@en
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@nl
prefLabel
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@ast
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@en
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@nl
P2093
P50
P1433
P1476
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
@en
P2093
Andrea Valentine
Anita Yakkundi
Christopher Byrne
Christopher Donley
David G Hirst
Hayley D McKeen
Helen O McCarthy
Martin O'Rourke
P304
P356
10.1158/0008-5472.CAN-09-2515
P407
P577
2010-01-26T00:00:00Z